- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.12.25 | Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 | 4 | GlobeNewswire (USA) | ||
| 17.12.25 | Longeveron receives patent for stem cell therapy targeting female sexual dysfunction | 2 | Investing.com | ||
| 17.12.25 | Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy | 1 | GlobeNewswire (USA) | ||
| 03.12.25 | Longeveron executives to speak at CVCT Forum on cell therapy trials | 1 | Investing.com | ||
| 03.12.25 | Longeveron: Führungskräfte präsentieren auf Fachforum für Zelltherapie-Studien | 1 | Investing.com Deutsch | ||
| LONGEVERON Aktie jetzt für 0€ handeln | |||||
| 03.12.25 | Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum | 1 | GlobeNewswire (USA) | ||
| 02.12.25 | Longeveron erhält kanadisches Patent für Stammzelltherapie | 1 | Investing.com Deutsch | ||
| 02.12.25 | Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging | 2 | GlobeNewswire (USA) | ||
| 01.12.25 | Longeveron's stem cell therapy shows reduced neuroinflammation in AD trial | 3 | Investing.com | ||
| 19.11.25 | Longeveron stellt Daten zur Alzheimer-Therapie auf der CTAD 2025 vor | 2 | Investing.com Deutsch | ||
| 19.11.25 | Longeveron to present Alzheimer's treatment data at CTAD 2025 | 1 | Investing.com | ||
| 12.11.25 | Longeveron secures patent for stem cell therapy targeting aging frailty | 2 | Investing.com | ||
| 12.11.25 | Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy | 420 | GlobeNewswire (Europe) | The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammagingNo approved... ► Artikel lesen | |
| 12.11.25 | Longeveron: Zwei Vorstandsmitglieder legen Ämter nieder | 4 | Investing.com Deutsch | ||
| 12.11.25 | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.11.25 | Longeveron GAAP EPS of -$0.39 misses by $0.13, revenue of $125M beats by $124.71M | 2 | Seeking Alpha | ||
| 04.11.25 | Longeveron Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 03.11.25 | Earnings Preview For Longeveron | 2 | Benzinga.com | ||
| 27.10.25 | Longeveron Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect | 1 | GlobeNewswire (USA) | ||
| 01.10.25 | Longeveron Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CUREVAC | 3,930 | -0,05 % | XFRA 5CV: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCUREVAC N.V. O.N.... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 50,50 | +1,41 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112) in Autoimmune Diseases and Hematologic Malignancies | -Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the... ► Artikel lesen | |
| OCUGEN | 1,340 | +0,71 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| EDITAS MEDICINE | 1,844 | +0,49 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| CYTODYN | 0,210 | 0,00 % | CytoDyn Inc.: December 2025 Letter to Shareholders | VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence and purpose into 2026, I want to extend my sincere appreciation for your... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,009 | -12,00 % | SOL Global Investments Corp.: SOL Global Announces Share Consolidation | Toronto, Ontario--(Newsfile Corp. - December 8, 2025) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL" or the "Company") announces that a majority vote by its Board of Directors... ► Artikel lesen | |
| TRINITY BIOTECH | 0,765 | +1,02 % | Trinity Biotech plc: Trinity Biotech Announces Agreements to Strengthen Capital Structure and Support Growth Initiatives | - Arrangements provide increased near-term funding and extend maturity of credit agreement to early 2027 - Equity settlement mechanisms also agreed for milestone payments and contingent acquisition... ► Artikel lesen | |
| FATE THERAPEUTICS | 0,833 | -4,03 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | ||
| ANAVEX LIFE SCIENCES | 3,534 | +2,85 % | Anavex Life Sciences Corp.: Anavex Life Sciences Receives FDA Feedback on Alzheimer's Disease Program | NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 6,600 | +3,53 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| CERUS | 1,789 | +0,73 % | Cerus Corporation: The German National Blood Advisory Committee Issues Formal Recommendation for Improving the Safety of Platelet Transfusions | Cerus Corporation (Nasdaq: CERS) announced today the publication of a new recommendation from the German National Blood Advisory Committee (Arbeitskreis Blut or AK Blut), which recommends proactive... ► Artikel lesen | |
| OVID THERAPEUTICS | 1,530 | +1,32 % | Ovid Therapeutics Inc.: Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer | NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need,... ► Artikel lesen | |
| WINDTREE THERAPEUTICS | 0,108 | -1,82 % | Windtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech Space | Windtree is executing its corporate strategy to diversify its business with revenue and profit generating divisions CommLoan, Inc. is a tech company focused on transforming the way middle market loans... ► Artikel lesen | |
| APTEVO THERAPEUTICS | 7,950 | 0,00 % | XFRA AP82: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAPTEVO THER.12/25... ► Artikel lesen | |
| HARVARD BIOSCIENCE | 0,585 | -1,68 % | Harvard Bioscience, Inc.: Harvard Bioscience Announces the Successful Completion of Debt Refinancing with Comprehensive Growth Financing Package | Completes Repayment of Existing Credit Agreement, Extends Debt Maturity, and Enhances Financial FlexibilityBroadOak Partner Bill Snider to Join Board of Directors and Company to Form Advisory Board... ► Artikel lesen |
Das Unternehmen LONGEVERON INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,581 Euro und damit +2,87 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LONGEVERON INC finden Sie auf Wallstreet Online.